

PEDIATRIC COMMUNITY ACQUIRED PNEUMONIA TREATMENT GUIDELINE

Guidelines for treatment of community-acquired pneumonia (CAP) in pediatric patients 0-18 years of age

- Outpatient/Emergency Department Setting

Specific Circumstances	Recommended Therapy	Duration
First line treatment	Amoxicillin 30mg/kg/dose TID (Max: 4g/day)	5 days
Could consider if: 1) Recent treatment with amoxicillin 2) Immunizations not up to date	Amoxicillin-clavulanate 30mg/kg/dose TID (amox component) (Max: 4g/day)	5 days
Suspect atypical organisms (i.e. Mycoplasma)	Azithromycin 10mg/kg/dose x 1 on day 1 (Max: 500mg), 5mg/kg/dose q24h days 2-5 (Max 250mg)	5 days
Penicillin allergy (anaphylaxis suspected)	Doxycycline 2mg/kg/dose BID if age greater than 7 years (Max: 100mg/dose) OR Levofloxacin 8-10mg/kg/dose BID age 6mo- less than 5 yrs; 8-10mg/kg/dose QD if greater than or equal to 5 years (Max 750mg/dose) OR Clindamycin 10-13 mg/kg/dose TID (Max 600mg/dose)	5 days
Non-serious penicillin allergy (anaphylaxis unlikely)	Cefpodoxime 5mg/kg/dose BID (Max:200mg/dose) if available at Pavillion pharmacy	5 days

- Inpatient Setting

First line therapy	Ampicillin 50mg/kg/dose IV q6h (Max: 1000g/dose)	5-7 days -Step down to amox when ready for d/c (see above)
1) Immunizations not up to date 2) non-serious penicillin (PCN) allergy (anaphylaxis unlikely) 3) severe or progressive pneumonia	Ceftriaxone 75mg/kg/dose IV q24h (Max: 2000g/dose)	5-7 days -Step down to amox-clavulanate – see dosing above. If concern for PCN allergy, please see other options above.
Suspect atypicals	Add: Azithromycin 10mg/kg/dose IV/PO x 1 on day 1 (Max: 500mg), 5mg/kg/dose IV/PO on days 2-5 (Max: 250mg)	5 days
Penicillin allergy (anaphylaxis suspected)	Doxycycline 2mg/kg/dose PO/IV q12h if age greater than 7 years (Max: 100mg/dose) OR Levofloxacin 8-10mg/kg/dose PO/IV q12h age 6mo – less than 5 yrs; 8-10mg/kg/dose PO/IV q24h if greater than or equal to 5 yrs (Max: 750mg/day) OR Clindamycin 10mg/kg/dose IV/PO q6h (Max: 600mg/dose)	5-7 days
1) Influenza and PICU admission 2) known MRSA colonization 3) severe or progressive pneumonia	Consider adding: Vancomycin 10-15mg/kg/dose IV q6h OR Clindamycin 10mg/kg/dose IV/PO q6h (Max 600mg/dose) OR Linezolid 10mg/kg/dose IV/PO q8h if age less than 12y or q12h if age greater than or equal to 12y(Max 600mg/dose)	Consider discontinuation after 48-72 hours based on patient’s clinical course and MRSA nares swab result
Necrotizing pneumonia or empyema	Please see empyema guideline or consult pediatric infectious disease	Typically 2-4 weeks

Medical Legal Disclaimer:

Welcome to the UC Davis Health, Department of Pediatrics, Clinical Practice Guidelines Website. All health and health-related information contained within the Site is intended chiefly for use as a resource by the Department's clinical staff and trainees in the course and scope of their approved functions/activities (although it may be accessible by others via the internet). This Site is not intended to be used as a substitute for the exercise of independent professional judgment. These clinical pathways are intended to be a guide for practitioners and may need to be adapted for each specific patient based on the practitioner's professional judgment, consideration of any unique circumstances, the needs of each patient and their family, and/or the availability of various resources at the health care institution where the patient is located. Efforts are made to ensure that the material within this Site is accurate and timely but is provided without warranty for quality or accuracy. The Regents of the University of California; University of California, Davis; University of California, Davis, Health nor any other contributing author is responsible for any errors or omissions in any information provided or the results obtained from the use of such information. Some pages within this Site, for the convenience of users, are linked to or may refer to websites not managed by UC Davis Health. UC Davis Health does not control or take responsibility for the content of these websites, and the views and opinions of the documents in this Site do not imply endorsement or credibility of the service, information or product offered through the linked sites by UC Davis Health. UC Davis Health provides limited personal permission to use the Site. This Site is limited in that you may not:

- Use, download or print material from this site for commercial use such as selling, creating course packets, or posting information on another website.
- Change or delete propriety notices from material downloaded or printed from it. · Post or transmit any unlawful, threatening, libelous, defamatory, obscene, scandalous, inflammatory, pornographic, or profane material, any propriety information belonging to others or any material that could be deemed as or encourage criminal activity, give rise to civil liability, or otherwise violate the law.
- Use the Site in a manner contrary to any applicable law.

You should assume that everything you see or read on this Site is copyrighted by University of California or others unless otherwise noted. You may download information from this Site as long as it is not used for commercial purposes, and you retain the proprietary notices. You may not use, modify, make multiple copies, or distribute or transmit the contents of this Site for public or commercial purposes without the express consent of UC Davis Health.